Argenx
ARGX
#443
Rank
A$78.65 B
Marketcap
A$1,259
Share price
0.18%
Change (1 day)
40.77%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2026 (TTM): A$2.23 Billion

According to Argenx 's latest financial reports the company's current earnings are A$4.66 Billion. In 2025 the company made an earning of A$1.81 Billion, an increase over its 2024 earnings that were of A$0.12 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$2.23 B22.96%
2025 A$1.81 B1400.64%
2024 A$0.12 B-127.97%
2023 -A$0.44 Billion-58.25%
2022 -A$1.04 Billion80.17%
2021 -A$0.58 Billion
2019 -A$0.29 Billion124.86%
2018 -A$0.13 Billion131.81%
2017 -A$54.32 Million
2015 -A$26.23 Million
2013 -A$15.87 Million